Other GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio PharmaphorumA court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli.Read full story pharminent April 27, 2026 (Last updated: April 27, 2026) Pharmaphorum A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli. Read full story Post navigation Previous: Rejuvenate crowdfunds development of gene therapy for aging, chronic diseasesNext: Jazz Pharmaceuticals receives FDA Priority Review for Ziihera combo in first-line HER2+ GEA Related Stories Other ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer pharminent June 2, 2026 Other ASCO26: Symptom-tracking app helps advanced cancer patients pharminent June 2, 2026 Other All eyes on Revolution, bispecific antibodies and more at ASCO26 pharminent May 26, 2026
